Pfizer Aktie News

Pfizer's deep pipeline could prove its greatest asset, helping it bounce back. Viking Therapeutics is developing a highly promising weight loss medicine.

Pfizer (PFE) remains a 'Buy' ahead of its fiscal Q1 2027 earnings, with the stock deeply discounted and consensus estimates overly pessimistic. LOE headwinds are significant but phased, while cost savings ($7.7B by 2027) and pipeline catalysts offer margin and revenue offsets. Pipeline momentum—especially in obesity, oncology, and vaccines—could drive narrative shifts and repricing if key 2026 ...

Pfizer's financial results over the next few years likely won't be strong. But the drug giant's pipeline progress could help it bounce back eventually.

Top ten ReFa/Ro Dogs are projected to deliver 25.77%–52.74% net gains by December 2026, with an average net gain of 34.55% and risk 62% below the market. Nine of the top ten ReFa/Ro Dogs have annual dividends from $1,000 invested exceeding their share price, meeting the 'ideal' dividend dogcatcher criteria. Analyst targets indicate the five lowest-priced, highest-yield ReFa/Ro Dogs could delive...

Shares of the pharmaceutical giant trade at less than 9 times its future earnings. Investors are likely concerned about upcoming patent cliffs that may weigh down its financials.

Pfizer is investing in oncology and GLP-1 drugs, among other things, to keep its growth prospects bright. Western Union is planning a digital network featuring a stablecoin.

Drug pricing, looming patent cliffs, dealmaking, and the first year of the second Trump administration dominated conversations at the annual JPMorgan Healthcare Conference in San Francisco.  Top executives from drugmakers of all sizes met with investors to map out their plans for 2026 and beyond.

Novavax Inc. (NASDAQ:NVAX) shares are up 3.3% to trade at $8.27 at last glance, after the vaccine company  singed a licensing agreement -- worth up to $500 million, including a $30 million upfront payment -- with Pfizer (PFE) for use of its Matrix-M adjuvant for up to two disease areas.